BioAge Labs (BIOA) vs Perspective Therapeutics (CATX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BioAge Labs (BIOA) has outperformed Perspective Therapeutics (CATX) over the past year, gaining 11.8% versus a loss of 29.1%. BioAge Labs is the larger company by market cap ($279.7 million vs $276.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIOA | CATX |
|---|---|---|
| Share price | $6.10 | $2.42 |
| Market cap | $279.74M | $276.13M |
| 1-day change | -2.64% | -1.67% |
| YTD return | -52.68% | -10.55% |
| 1-year return | +11.79% | -29.11% |
| 5-year return | — | -60.32% |
| EPS (TTM) | $-2.39 | $-1.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $25.96 | $6.16 |
| 52-week low | $5.04 | $1.96 |
| Distance from 52-week high | -76.52% | -60.73% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +484.58% | +408.06% |
| Average volume | 913.77K | 1.67M |
| Shares outstanding | 45.90M | 114.15M |
| Employees | 60 | 163 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BIOA has outperformed CATX by 40.9 percentage points over the past year.
About BioAge Labs
BIOA stock →BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.
Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees
About Perspective Therapeutics
CATX stock →Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.
Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees
BIOA vs CATX FAQ
Which is bigger, BioAge Labs or Perspective Therapeutics?
BioAge Labs (BIOA) is larger, with a market capitalization of $279.74M compared with $276.13M for Perspective Therapeutics (CATX).
Which stock has performed better over the past year, BIOA or CATX?
BIOA returned +11.79% over the past 12 months, compared with -29.11% for CATX (price return, excluding dividends). Past performance does not predict future results.
Are BioAge Labs and Perspective Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.